Papers/PMID:41364169
Assessment of the effectiveness and safety of two-month oral supplementation with L-arginine depending on the type of lipid metabolism disorder in patients with atherosclerotic lower limb ischemia.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
L-arginine — increases total antioxidant capacity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After 30 and 60 days, significant increases in NO and TAS levels (p<0.001), as well as extended PFWD (p<0.001), were observed across all subgroups receiving L-arginine compared with controls.”
Quoted verbatim from Assessment of the effectiveness and safety of two-month oral supplementation with L-arginine depending on the type of lipid metabolism disorder in patients with atherosclerotic lower limb ischemia.. - Study
- RCT
- Dose
- 6 g/day, oral, for 30 and 60 days
- Population
- Patients over 50 years of age with Fontaine stage II atherosclerotic lower limb ischemia (hypertriglyceridemia, hypercholesterolemia and mixed hyperlipidemia subgroups)
Assessment of the effectiveness and safety of two-month oral supplementation with L-arginine depending on the type of lipid metabolism disorder in patients with atherosclerotic lower limb ischemia.2025PMID:41364169Permalink